Related Experiment Video

Updated: Jun 1, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy

Michela Pasello1, Maria Cristina Manara, Francesca Michelacci

  • 1Rizzoli Orthopaedic Institute, Laboratory of Experimental Oncology, Bologna, Italy.

Analytical Cellular Pathology (Amsterdam)
|June 16, 2011
PubMed

Insights

Targeting glutathione-S-transferase (GST) enzymes with NBDHEX shows promise for treating osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. This approach enhances chemotherapy efficacy, particularly in drug-resistant musculoskeletal tumors.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Musculoskeletal tumors like osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma often exhibit resistance to conventional chemotherapy.
  • Glutathione-S-transferase (GST) isoenzymes play a role in drug resistance in these cancers.

Purpose of the Study:

  • To evaluate the efficacy of the GST-targeting agent NBDHEX against common musculoskeletal tumors.
  • To assess the relationship between NBDHEX activity and GST isoenzyme expression.
  • To investigate NBDHEX's synergistic or antagonistic effects with conventional chemotherapeutic agents.

Main Methods:

  • Utilized a panel of 15 drug-sensitive and drug-resistant human osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma cell lines.
  • Assessed the in vitro activity of NBDHEX and correlated it with GST isoenzyme expression (GSTP1, GSTA1, GSTM1, MGST).
  • Performed in vivo studies in Ewing's sarcoma models and evaluated effects on osteosarcoma cell metastasis.

Main Results:

  • NBDHEX demonstrated significant in vitro activity against all tested cell lines, including drug-resistant ones with high GST levels.
  • NBDHEX primarily induced cytostatic effects rather than apoptosis.
  • Positive interactions were observed with doxorubicin, vincristine, and cisplatin, while antagonism occurred with methotrexate.
  • In vivo studies confirmed NBDHEX's cytostatic efficacy and synergy with vincristine in Ewing's sarcoma, and showed an effect against osteosarcoma metastasis.

Conclusions:

  • Targeting GSTs with NBDHEX represents a potential novel therapeutic strategy for osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
  • This approach may benefit patients with limited response to current chemotherapy regimens.
  • NBDHEX shows promise as an adjunct therapy to overcome drug resistance in musculoskeletal cancers.

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...